	US 12,221,473 B2
	Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
Bridget Puffer, South Weymouth, MA (US); Julian Chandler, Guilford, CT (US); Nimish Gera, Waltham, MA (US); Douglas L. Sheridan, Branford, CT (US); Siddharth Jindal, Hamden, CT (US); and Paul P. Tamburini, Kensington, CT (US)
Assigned to Alexion Pharmaceuticals, Inc., Boston, MA (US)
Filed by Alexion Pharmaceuticals, Inc., Boston, MA (US)
Filed on Oct. 7, 2022, as Appl. No. 17/938,756.
Application 17/938,756 is a continuation of application No. 16/629,687, granted, now 11,498,960, previously published as PCT/US2018/041661, filed on Jul. 11, 2018.
Claims priority of provisional application 62/531,215, filed on Jul. 11, 2017.
Prior Publication US 2023/0235033 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 38/47 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/18 (2013.01) [A61K 38/47 (2013.01); A61K 39/3955 (2013.01); C12Y 302/01035 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

13 Claims

1. An engineered polypeptide that specifically binds to human serum albumin, wherein the engineered polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:22-25 and 27-34 and fragments thereof.